Curated News
By: NewsRamp Editorial Staff
November 02, 2026
ABVC BioPharma Closes $3.39M Private Placement
TLDR
- ABVC BioPharma raised $3.39 million in a private placement to fund subsidiaries and settle a $625,000 payment, supporting its pharmaceutical and medical-device strategy.
- The 17.5% OID Notes have a principal of $4,106,060, mature June 30, 2027, and convert after eight months at 85% of the three-day VWAP.
- ABVC BioPharma's financing supports development of drugs for CNS and oncology and an eye device, aiming to improve patient care and health outcomes.
- ABVC BioPharma's convertible notes offer a unique investment structure, with conversion terms tied to VWAP and a settlement with Lind Global Fund II LP.
Impact - Why it Matters
This financing provides ABVC with immediate capital to address near-term obligations, including a $625,000 settlement with Lind Global Fund II LP, while supporting working capital and subsidiary funding. The convertible note structure, with an eight-month lock-up and conversion at a discount to VWAP, could lead to dilution, but the proceeds may also enable ABVC to advance its CNS, oncology, and ophthalmic programs and pursue licensing and financing opportunities for its dedicated platforms. For investors, the deal underscores the company’s ongoing need for capital and its efforts to strengthen its balance sheet as it develops a pipeline of six drugs and the Vitargus® medical device.
Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company, announced the closing of a private placement of original issue discount senior convertible promissory notes, generating aggregate gross proceeds of approximately $3.39 million before fees and expenses. The 17.5% OID Notes have an aggregate principal amount of $4,106,060, mature on June 30, 2027, and are convertible into common stock at 85% of the average of the three VWAPs for the three trading days prior to conversion, subject to a floor price. The offering was made to institutional and other accredited investors, with WallachBeth Capital, Inc. acting as placement agent and Hunter Taubman Fischer & Li LLC as legal counsel to the Company. Sichenzia Ross Ference Carmel LLP served as counsel to the placement agent.
The Company plans to use the net proceeds for general working capital, funding of its subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a definitive release and settlement agreement. This payment is expected to satisfy specified outstanding claims and support ABVC’s ability to pursue broader financing and business development initiatives. The offering is expected to advance ABVC’s strategy of developing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing. ABVC has established dedicated platforms: AiBtl BioPharma Inc. for central nervous system drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as an AI Biotechnology Innovation Platform.
ABVC is developing six new drugs in CNS and oncology, and one innovative medical device, ABV-1701/Vitargus®, for ophthalmology, utilizing in-licensed technology from research institutions including Stanford University, UCSF, and Cedars-Sinai Medical Center. The notes and underlying shares are not registered under the Securities Act of 1933 and may not be offered or sold in the U.S. absent registration or an exemption. Additional details will be available in the Company’s Current Report on Form 8-K filed with the SEC. The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, ABVC BioPharma Closes $3.39M Private Placement
